Hepatic Manifestations in Juvenile Systemic Lupus Erythematosus
Mortada H. El-Shabrawi and Mona I. Farrag
Affiliation: Faculty of Medicine, Cairo University, Cairo, Egypt, Postal Address: 3 Nablos Street, Off Shehab Street, Mohandesseen, Giza, 12411, Egypt.
Keywords: Autoimmune hepatitis, hepatic disorders, novel therapies, systemic lupus erythematosus.
Juvenile systemic lupus erythematosus (JSLE) is a chronic autoimmune disease characterized by multisystem
involvement and diverse clinical and serological manifestations. Clinically significant hepatic disease is generally
regarded as unusual in JSLE, but many studies have showed that hepatic disease may be more common in SLE than was
usually thought. Hepatic disease does not cause significant morbidity and mortality, but subclinical liver involvement is
common. One of the hepatic disorders associated with JSLE is autoimmune hepatitis (AIH). The precise etiology of
AIH and JSLE remains unknown, however both AIH and JSLE are associated with antinuclear antibody (ANA) and
multisystem disease manifestations. A shared immunologic response and genetic predisposition were suggested. Recently,
new approaches for treatment of SLE and recent patents that could develop into novel therapeutic agents in clinical
management of SLE have been proposed. An array of promising new therapies is currently emerging or being developed
including B-cell depletion therapies, agents targeting B-cell survival factors, blockade of T-cell co-stimulation and present
review, we will also report the case of a 12-year old girl who developed JSLE four years after her preliminary diagnosis
Rights & PermissionsPrintExport